$617 Million is the total value of VR Adviser, LLC's 27 reported holdings in Q1 2022. The portfolio turnover from Q4 2021 to Q1 2022 was 42.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ACRS | Aclaris Therapeutics Inc | $78,683,000 | +18.6% | 4,563,962 | 0.0% | 12.75% | +40.5% | |
| TIL | Instil Bio Inc | $73,800,000 | -37.2% | 6,865,076 | 0.0% | 11.96% | -25.5% | |
| RLMD | Relmada Therapeutics Inc | $61,269,000 | +19.8% | 2,270,072 | 0.0% | 9.93% | +42.0% | |
| TVTX | Travere Therapeutics Inc | $51,411,000 | -17.0% | 1,994,997 | 0.0% | 8.33% | -1.6% | |
| GHRS | Buy | GH Research PLCord sh | $37,514,000 | -20.5% | 2,051,060 | +1.4% | 6.08% | -5.7% |
| TCDA | Buy | Tricida Inc | $36,948,000 | +10.6% | 4,494,851 | +28.6% | 5.99% | +31.1% |
| VRDN | Viridian Therapeutics Inc | $34,260,000 | -6.5% | 1,852,919 | 0.0% | 5.55% | +10.8% | |
| Buy | Marinus Pharmaceuticals Inc | $29,516,000 | -13.7% | 3,156,803 | +9.6% | 4.78% | +2.2% | |
| CLDX | Celldex Therapeutics Inc | $29,466,000 | -11.9% | 865,116 | 0.0% | 4.77% | +4.5% | |
| Aadi Bioscience Inc | $25,954,000 | -29.7% | 1,529,402 | 0.0% | 4.20% | -16.7% | ||
| KDNY | Chinook Therapeutics Inc | $21,003,000 | +0.3% | 1,283,821 | 0.0% | 3.40% | +18.9% | |
| LianBiospons adr | $19,954,000 | -39.8% | 5,378,341 | 0.0% | 3.23% | -28.6% | ||
| VTGN | VistaGen Therapeutics Inc | $19,899,000 | -36.4% | 16,047,286 | 0.0% | 3.22% | -24.6% | |
| ATHA | Athira Pharma Inc | $13,500,000 | +3.6% | 1,000,000 | 0.0% | 2.19% | +22.8% | |
| EIGR | New | Eiger BioPharmaceuticals Inc | $12,199,000 | – | 1,469,767 | +100.0% | 1.98% | – |
| Nuvalent Inc | $11,167,000 | -27.0% | 803,951 | 0.0% | 1.81% | -13.5% | ||
| GRPH | Graphite Bio Inc | $8,224,000 | -59.0% | 1,612,617 | 0.0% | 1.33% | -51.4% | |
| PRVB | New | Provention Bio Inc | $8,189,000 | – | 1,118,653 | +100.0% | 1.33% | – |
| COGT | Cogent Biosciences Inc | $8,155,000 | -12.7% | 1,088,817 | 0.0% | 1.32% | +3.4% | |
| LIFE | Sell | aTyr Pharma Inc | $7,484,000 | -36.0% | 1,398,889 | -10.6% | 1.21% | -24.2% |
| AFMD | Affimed NV | $6,243,000 | -20.8% | 1,428,571 | 0.0% | 1.01% | -6.2% | |
| SRRA | New | Sierra Oncology Inc | $5,207,000 | – | 162,479 | +100.0% | 0.84% | – |
| ALT | New | Altimmune Inc | $4,627,000 | – | 759,719 | +100.0% | 0.75% | – |
| CNTA | Sell | Centessa Pharmaceuticals PLCspons adr | $3,690,000 | -70.9% | 411,361 | -63.5% | 0.60% | -65.5% |
| Astria Therapeutics Inc | $3,617,000 | +24.5% | 538,999 | 0.0% | 0.59% | +47.6% | ||
| AVTE | New | Aerovate Therapeutics Inc | $2,769,000 | – | 151,037 | +100.0% | 0.45% | – |
| SVRA | New | Savara Inc | $2,496,000 | – | 1,905,265 | +100.0% | 0.40% | – |
| CRVS | Exit | Corvus Pharmaceuticals Inc | $0 | – | -250,000 | -100.0% | -0.08% | – |
| AKYA | Exit | Akoya Biosciences Inc | $0 | – | -400,000 | -100.0% | -0.84% | – |
| CVRX | Exit | CVRx Inc | $0 | – | -533,370 | -100.0% | -0.89% | – |
| OLMA | Exit | Olema Pharmaceuticals Inc | $0 | – | -816,651 | -100.0% | -1.04% | – |
| KNTE | Exit | Kinnate Biopharma Inc | $0 | – | -773,014 | -100.0% | -1.87% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-05-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ACLARIS THERAPEUTICS INC | 12 | Q3 2023 | 12.7% |
| VIRIDIAN THERAPEUTICS INC | 12 | Q3 2023 | 13.4% |
| COGENT BIOSCIENCES INC | 12 | Q3 2023 | 10.3% |
| RELMADA THERAPEUTICS INC | 11 | Q3 2022 | 9.9% |
| GH RESEARCH PLC | 10 | Q3 2023 | 6.7% |
| ALTIMMUNE INC | 9 | Q3 2022 | 11.6% |
| MARINUS PHARMACEUTICALS INC | 9 | Q4 2022 | 5.7% |
| CELLDEX THERAPEUTICS INC | 9 | Q3 2022 | 7.6% |
| AFFIMED N V | 8 | Q3 2023 | 1.1% |
| INSTIL BIO INC | 7 | Q3 2022 | 18.7% |
View VR Adviser, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-11 |
| 13F-HR/A | 2023-05-15 |
| 13F-HR/A | 2023-05-15 |
| 13F-HR/A | 2023-05-15 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
View VR Adviser, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.